Skip to content

Source filing unavailable

Q2 2016 · —
Revenue$381.16M+14.2% vs Q2 2015+13.4% vs Q1 2016
Net Income$114.50M+29.9% vs Q2 2015+51.0% vs Q1 2016
EPS Diluted$1.85+32.1% vs Q2 2015+52.9% vs Q1 2016
Gross Profit$355,130,000+14.4%
Operating Income$168,735,000+10.1%
Operating Cash Flowderived$127,014,000−9.6%
Free Cash Flowderived$123,458,000−3.2%
Margins · derived
Gross margin93.2%+0.2 pt vs Q2 2015
Operating margin44.3%−1.7 pt vs Q2 2015
Net margin30.0%+3.6 pt vs Q2 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2016Q2 2015Q2 2014Q2 2013
Revenue$381.16M$333.75M$291.23M$208.25M
Net Income$114.50M$88.11M$43.66M$42.19M
EPS Diluted$1.85$1.40$0.70$0.69

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR